Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating and $36 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX: